PMID- 33438359 OWN - NLM STAT- MEDLINE DCOM- 20220131 LR - 20220131 IS - 1755-3768 (Electronic) IS - 1755-375X (Linking) VI - 99 IP - 7 DP - 2021 Nov TI - Inflammatory cytokines levels in aqueous humour and surgical outcomes of trabeculectomy in patients with prior acute primary angle closure. PG - e1106-e1111 LID - 10.1111/aos.14763 [doi] AB - PURPOSE: To quantify the levels of three inflammatory cytokines in the aqueous humour of patients with prior acute primary angle closure (APAC) and investigate their correlation with surgical outcomes of trabeculectomy. METHODS: In this prospective cohort study, aqueous humour samples were collected from 44 prior APAC eyes. Analyte concentrations of monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) were measured using multiplexed immunoassay kits. Intraocular pressure was measured using Goldmann application tonometry. RESULTS: Forty-four prior APAC eyes were followed up for 24 months after trabeculectomy and divided into success and failure groups according to surgical outcomes. Monocyte chemoattractant protein-1 (MCP-1) levels in the aqueous humour were significantly higher in the failure group (p = 0.0118). Univariate and multivariate analyses showed that MCP-1 level was a significant risk factor for trabeculectomy outcomes (univariate analysis: p = 0.016, odds ratio = 14.538; multivariate analysis: p = 0.023, odds ratio = 13.718). When prior APAC eyes were divided according to MCP-1 levels, the overall success rate was significantly higher in eyes with low MCP-1 levels than eyes with high MCP-1 levels (p = 0.0249). CONCLUSION: In prior APAC patients, the MCP-1 level in the aqueous humour predicts trabeculectomy results. Therefore, modulation of MCP-1 expression may have potential clinical applications after filtration surgery. CI - (c) 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. FAU - Yu, Ping AU - Yu P AD - Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. AD - National Clinical Research Center for Eye Diseases, Shanghai, China. AD - Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China. AD - Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China. AD - Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Disease, Shanghai, China. AD - Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Qian, Tianwei AU - Qian T AUID- ORCID: 0000-0002-7359-911X AD - Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. AD - National Clinical Research Center for Eye Diseases, Shanghai, China. AD - Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China. AD - Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China. AD - Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Disease, Shanghai, China. FAU - Gong, Qiaoyun AU - Gong Q AD - Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. AD - National Clinical Research Center for Eye Diseases, Shanghai, China. AD - Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China. AD - Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China. AD - Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Disease, Shanghai, China. FAU - Fu, Mingshui AU - Fu M AD - Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. AD - National Clinical Research Center for Eye Diseases, Shanghai, China. AD - Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China. AD - Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China. AD - Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Disease, Shanghai, China. FAU - Bian, Xiaolan AU - Bian X AD - Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Sun, Tao AU - Sun T AD - Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. AD - National Clinical Research Center for Eye Diseases, Shanghai, China. AD - Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China. AD - Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China. AD - Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Disease, Shanghai, China. FAU - Zhang, Zhihua AU - Zhang Z AUID- ORCID: 0000-0003-0122-2070 AD - Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. AD - National Clinical Research Center for Eye Diseases, Shanghai, China. AD - Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China. AD - Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China. AD - Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Disease, Shanghai, China. FAU - Xu, Xun AU - Xu X AUID- ORCID: 0000-0002-4246-4343 AD - Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. AD - National Clinical Research Center for Eye Diseases, Shanghai, China. AD - Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China. AD - Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China. AD - Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Disease, Shanghai, China. LA - eng GR - 81600704/National Natural Science Foundation of China/ GR - 81800878/National Natural Science Foundation of China/ PT - Journal Article DEP - 20210113 PL - England TA - Acta Ophthalmol JT - Acta ophthalmologica JID - 101468102 RN - 0 (Biomarkers) RN - 0 (Cytokines) SB - IM MH - Acute Disease MH - Aged MH - Aqueous Humor/*metabolism MH - Biomarkers/metabolism MH - Cytokines/metabolism MH - Female MH - Follow-Up Studies MH - Glaucoma, Angle-Closure/*metabolism/physiopathology/surgery MH - Humans MH - Immunoassay MH - Intraocular Pressure/*physiology MH - Male MH - Prospective Studies MH - Trabeculectomy/*methods MH - Treatment Outcome OTO - NOTNLM OT - acute primary angle closure OT - inflammatory cytokine OT - monocyte chemotactic protein-1 OT - trabeculectomy EDAT- 2021/01/14 06:00 MHDA- 2022/02/01 06:00 CRDT- 2021/01/13 06:19 PHST- 2020/10/02 00:00 [revised] PHST- 2020/05/22 00:00 [received] PHST- 2020/12/20 00:00 [accepted] PHST- 2021/01/14 06:00 [pubmed] PHST- 2022/02/01 06:00 [medline] PHST- 2021/01/13 06:19 [entrez] AID - 10.1111/aos.14763 [doi] PST - ppublish SO - Acta Ophthalmol. 2021 Nov;99(7):e1106-e1111. doi: 10.1111/aos.14763. Epub 2021 Jan 13.